Renal Failure News and Research RSS Feed - Renal Failure News and Research

Renal failure or kidney failure is where the kidneys fail to function adequately. Renal failure is divided in acute and chronic forms; either form may be due to a large number of other medical problems.
Research finding could lead to new therapeutic target for treating hypertension in males

Research finding could lead to new therapeutic target for treating hypertension in males

Higher levels of a "danger" molecule may be one reason males tend to become hypertensive earlier and more severely than females, scientists say. [More]
Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC

Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC

Eisai Inc. announced today that the U.S. Food and Drug Administration approved the company's receptor tyrosine kinase inhibitor LENVIMA (lenvatinib) for the treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC). [More]
Scientists identify new cellular pathway affected in cystinosis

Scientists identify new cellular pathway affected in cystinosis

Scientists at The Scripps Research Institute have identified a new cellular pathway that is affected in cystinosis, a rare genetic disorder that can result in eye and kidney damage. [More]
Doctors carry out first organ transplant from UK newborn

Doctors carry out first organ transplant from UK newborn

The very first successful organ donation from a newborn carried out in the UK is reported in the Fetal & Neonatal Edition of Archives of Disease in Childhood. [More]
Asian and Hispanic patients with lupus have lower mortality rates

Asian and Hispanic patients with lupus have lower mortality rates

A new study by researchers from Brigham and Women's Hospital in Boston, Massachusetts reveals that Asian and Hispanic patients with systemic lupus erythematosus (SLE) have lower mortality rates compared to Black, White, or Native Americans with the disease. [More]
3SBio, PharmAbcine sign licensing agreement to develop and market DIG-KT

3SBio, PharmAbcine sign licensing agreement to develop and market DIG-KT

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive licensing deal with PharmAbcine Inc. for the development, manufacturing and marketing of DIG-KT, a bi-specific monoclonal antibody ("mAb") targeting both VEGFR2/KDR and Tie-2 pathways for cancer in the territory of Greater China (including mainland China, Taiwan, Hong Kong and Macau) and Korea. [More]
Periods of extreme heat associated with increased hospitalization risk for older adults

Periods of extreme heat associated with increased hospitalization risk for older adults

Between 1999 and 2010, periods of extreme heat in the U.S. were associated with an increased risk of hospitalization for older adults for fluid and electrolyte disorders, kidney failure, urinary tract infections, septicemia and heat stroke, according to a study in the December 24/31 issue of JAMA. [More]
IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL

IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL

New IMBRUVICA (ibrutinib) Phase II data announced by Pharmacyclics, Inc. today demonstrates its potential utility as a combination therapy when used with rituximab. Data suggest that the overall efficacy and safety profile of IMBRUVICA is well tolerated when combined with rituximab in patients with relapsed or refractory mantle cell lymphoma (MCL). [More]
Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Results from the Phase 2 RESONATE-17 (PCYC-1117) study show IMBRUVICA (ibrutinib) was associated with an 82.6 percent investigator-assessed overall response rate (ORR; the primary endpoint) and a 79 percent progression-free survival (PFS) rate at 12 months in people living with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have a genetic mutation known as deletion 17p (del 17p). [More]
Amgen's XGEVA (denosumab) receives FDA approval for treatment of hypercalcemia of malignancy

Amgen's XGEVA (denosumab) receives FDA approval for treatment of hypercalcemia of malignancy

Amgen today announced that the U.S. Food and Drug Administration has approved a new indication for XGEVA (denosumab) for the treatment of hypercalcemia of malignancy (HCM) refractory to bisphosphonate therapy. [More]
IMBRUVICA demonstrates anti-tumor activity against multiple myeloma in Phase II study

IMBRUVICA demonstrates anti-tumor activity against multiple myeloma in Phase II study

New IMBRUVICA (ibrutinib) Phase II data announced here today by Pharmacyclics, Inc) during the 56th American Society of Hematology Annual Meeting suggests that IMBRUVICA demonstrates anti-tumor activity both as a single-agent and as combination therapy in heavily pre-treated patients with relapsed or relapsed/refractory multiple myeloma (MM). [More]
New therapeutic targets can prevent scarring within transplanted kidneys

New therapeutic targets can prevent scarring within transplanted kidneys

Kidneys donated by people born with a small variation in the code of a key gene may be more likely, once in the transplant recipient, to accumulate scar tissue that contributes to kidney failure, according to a study led by researchers at the Icahn School of Medicine at Mount Sinai and published today in the Journal of Clinical Investigation. [More]
Scientists unravel molecular mechanisms that drive ferroptosis signaling

Scientists unravel molecular mechanisms that drive ferroptosis signaling

Ferroptosis is a recently recognized form of regulated necrosis. Up until now, this form of cell death has only been thought to be a possible therapeutic approach to treat tumour cells. Yet, ferroptosis also occurs in non-transformed tissues as demonstrated by this study, thus implicating this cell death pathway in the development of a wide range of pathological conditions. More specifically, the deletion of the ferroptosis-regulating enzyme Gpx4 in a pre-clinical model results in high ferroptosis rates in kidney tubular epithelial cells causing acute renal failure. [More]
3SBio enters into exclusive license agreement with PharmAbcine for Tanibirumab

3SBio enters into exclusive license agreement with PharmAbcine for Tanibirumab

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with PharmAbcine, Inc. for the development, manufacturing and marketing of Tanibirumab, an anti-VEGFR2/KDR antibody for cancer in the territory of Greater China (including Mainland China, Taiwan, Hong Kong and Macau) and several emerging countries, including Thailand, Brazil and Russia. [More]
Denmark researchers calculate the real burden of foodborne infections

Denmark researchers calculate the real burden of foodborne infections

Campylobacter is the foodborne bacteria that contributes most to the burden of disease in Denmark. This is the finding of a study from the National Food Institute, Technical University of Denmark, which for the first time in Denmark ranks three foodborne bacteria according to the burden of disease they impose on society as a whole. [More]
Wimpy antibody prevents more serious self-inflicted forms of kidney disease, researchers say

Wimpy antibody prevents more serious self-inflicted forms of kidney disease, researchers say

An antibody abundant in mice and previously thought to offer poor assistance in fighting against infection may actually play a key role in keeping immune responses in check and preventing more serious self-inflicted forms of kidney disease, researchers say. [More]
Aortic valve replacement is safe to treat severe aortic stenosis in very eldery patients

Aortic valve replacement is safe to treat severe aortic stenosis in very eldery patients

Aortic valve replacement (AVR) can safely be used to treat severe aortic stenosis in patients age 90 years and older and is associated with a low risk of operative stroke and mortality, according to a study in the November 2014 issue of The Annals of Thoracic Surgery. [More]
Preeclampsia study provides pathways for new therapeutic treatments

Preeclampsia study provides pathways for new therapeutic treatments

A team of researchers led by a Wayne State University School of Medicine associate professor of obstetrics and gynecology has published findings that provide novel insight into the cause of preeclampsia, the leading cause of maternal and infant death worldwide, a discovery that could lead to the development of new therapeutic treatments. [More]
Janssen announces submission of IMBRUVICA sNDA to FDA for WM treatment

Janssen announces submission of IMBRUVICA sNDA to FDA for WM treatment

Janssen Research & Development, LLC today announced the submission of a supplemental New Drug Application (sNDA) for IMBRUVICA (ibrutinib) to the U.S. Food and Drug Administration by its strategic partner Pharmacyclics, Inc. [More]
Newly developed agent filters out toxins from body in the event of overdose

Newly developed agent filters out toxins from body in the event of overdose

Every minute counts in the event of an overdose. ETH professor Jean-Christophe Leroux and his team have developed an agent to filter out toxins from the body more quickly and efficiently. [More]